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ABSTRACT 
Electronic Common Technical Document (eCTD) is a topic of increasing interest in the pharmaceutical Industry as it become compulsory for 
filing procedures.  The Common Technical Document (CTD) is a set of specification for application dossier, for the registration of Medicines and 
designed to be used across Europe, Japan and the United States.Quality, Safety and Efficacy information is assembled in a common 
format through CTD .The CTD is maintained by the International Conference on Harmonisation of Technical Requirements for Registration of 
Pharmaceuticals for Human Use (ICH). Electronic common technical documentis an interface used by applicants of marketing authorisation for 
medical products to submit regulatory affairs document to the agency concerned. The purpose of this article is to present a concise overview of 
challenges faced during eCTD & CTD submissions in United States and Canada. A regulatory process, by which a person/organization/ 
sponsor/innovator gets authorization to launch a drug in the market, is known as registration process. The registration process will be done by 
submitting technical information to the authority 
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Introduction: 
The concept of electronic regulatory submissions is not new, 
and has been evolving in America and Europe since the late 
1980s. The Food and Drug Administration (FDA) and others 
has worked with electronic submissions for more than a 
decade CANDA –(Computer Aided New Drug Application), 
Initiated in 1985 by FDA in US.  
According to FDA it is efficient and high-quality analysis of 
data. Unfortunately, the CANDA era led to a proliferation of 
unique and proprietary formats for CANDAs, most of which 
required a stand-alone desktop computer on the desk of each 
regulatory reviewer. A whole variety of strategies for 
CANDAs emerged, from simple to complex. Each CANDA 
required a reviewer to learn a new system for accessing the 
data, a daunting task in many cases that few reviewers had 
time for. There were no standards for the structure of a 
CANDA and no common software platform or file format for 
the data. The results were mixed, many reviewers and 
sponsors were delighted with the efficient review that 
CANDAs provided, but others were unwilling to train on and 
use multiple different systems, sometimes simultaneously. 
The FDA soon called a halt to the unstructured CANDA 
era.But this was certainly not the end of the submission of 
electronic data.  
DAMOS-Drug Application Methodology with Optical Storage; 
Initiated by European regulatory Europe in 1989.  
SEDAMM - SoumissionElectronique de Dossiers 
d'Autorisation de Misesur le Marché; Initiated by France in 
1993.   
MERS- Multiagency Electronic Regulatory Submission 
Project; Initiated by USA, Newzea land, and Australia in 
1994.  
MANSEV - Market Authorisation by Network Submission and 
Evaluation; Initiated by UK, Denmark, France, Italy and 
EMEA in 1997.  
In 1997, ICH M2 Expert Working Group (EWG) started 
working closely with M4 (CTD), the ICH guideline that 
presents the agreed upon common format for the 
preparation of a well-structured Common Technical 
Document for applications that will be submitted to 
regulatory authorities.  
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Simultaneously the FDA revealed the beginnings of a new 
method of electronic submission. The increasing volume of 
NDAs and the need for expedited review caused by the 1992 
Prescription Drug User Fee Act (PDUFA) initiatives 
demanded that the FDA develop an approach for the efficient 
review of electronic data. The FDA was looking for a way to 
deal with the accumulating volumes of paper in its file rooms 
and the logistical problem of distributing sections of 
regulatory submissions to appropriate reviewers. By means 
of a series of guidance documents, the agency intended to 
carefully define the structure and technology that was 
acceptable for electronic submissions. In this way, the FDA 
could ensure a consistent set of electronic submission 
documents and reviewers could be comfortable that any 
electronically submitted data would be viewable in a familiar 
format. As a result, in 2002, eNDA and eANDAGuidance 
issued by FDA. Shortly after the first guidance documents 
were issued, electronic submission of New Drug 
Application(NDA) and Abbreviated New Drug 
Application(ANDA) documents became an emerging 
standard for many pharmaceutical sponsors, eliminating the 
need for manual printing, duplication, pagination, and other 
processes.  
A significant milestone was the adoption in 2003 of the ICH 
eCTD Guideline v3.0 on the electronic Common Technical 
Document (eCTD), which is the electronic counterpart of the 
Common Technical Document (CTD; a harmonized structure 
and format for regulatory submissions).  
Common Technical Document 
Common Technical Document for applications that will be 
submitted to regulatory authorities. A common format for 
the technical documentation will significantly reduce the 
time and resources needed to compile applications for 
registration of human pharmaceuticals and will ease 
thepreparation of electronic submissions. Regulatory 
reviews and communication with the applicant will be 
facilitated by a standard document of common elements. In 
addition, exchange of regulatory information between 
Regulatory Authorities will be simplified 
The CTD is organised into five modules. Module 1 is region 
specific and Modules 2, 3, 4 and 5 are intended to be 
common for all regions. In July 2003, the CTD became the 
mandatory format for new drug applications in the EU and 
Japan, and the strongly recommended format of choice for 
NDAs submitted to the FDA, US. 
 
 
 
eCTD 
eCTD or electronic common technical document is an 
interface designed for the pharmaceutical industry to 
transfer regulatory information. This module-based 
regulatory application format was developed by 
the International Conference on Harmonization (ICH M2 
EWG). In 2008 the FDA (Food and Drug Administration) 
made eCTD format compulsory for all electronic 
submissions by FDA in 2008. 
The life sciences industry has been facing certain difficulties 
in regulatory processes. Even though the electronic common 
technical document has been of great help in managing huge 
volumes of important documentation; there are a few 
glitches that complicate the submission process for the 
organizations. In this post we’ll be discussing about 
those challenges faced by life sciences companies in eCTD 
submissions.  
The role of eCTD is to help pharmaceutical companies 
enhance the submission procedure by bridging the gap 
between the time and market and minimizing expenses. 
However, a recent analysis made by the Open Text™ Corp (a 
leading company in enterprise content management), it’s 
found out that most of the pharmaceutical companies are 
struggling hard to meet the deadline created by FDA to 
comply with the standard using eCTD format. 
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eCTD format enables pharmaceutical companies to submit 
applications to various regulatory authorities such as FDA 
without altering the data. This XML-based electronic version 
of the CTD is now widely used as preferred submission 
format for the US Food and Drug Administration (FDA) and 
the European Medicines Agency (EMA). 
eCTD format is now widely used in the United States, Japan, 
the European Union and Canada. As per Harv Martens, a 
member of the ICH M2 Expert Working Group, 
“Pharmaceutical companies handle huge amounts of 
documentation for regulatory submissions. The information 
gathering process is very costly. It causes delays and expense 
in the development of new drugs. The objective of the 
CTD/eCTD is to harmonize both the content and the way it is 
delivered for the new drug approval process.” 
theeCTD is a standardized arrangement of documents that 
allows for the consistent and comprehensive presentation of 
information within a submission. eCTD submissions include 
5 parts, termed modules, with each containing a specific type 
of information. 
• Module 1 (not technically part of the CTD): region-
specific administrative information 
• Module 2: manufacturing, nonclinical, and clinical 
overviews and summaries 
• Module 3: detailed manufacturing information 
• Module 4: nonclinical study reports 
• Module 5: clinical study reports 
Chemistry, Manufacturing, and Controls (CMC) 
As anyone who has written an IND or marketing application 
knows, the CMC modules (module 3 and summaries in 
module 2) are expansive and can be tedious and time-
consuming to complete. 
Because more documents typically mean more “cooks in the 
kitchen,” it is tempting to combine permitted sections in an 
effort to streamline the management of authors and 
versions. However, the granularity of CMC sections should 
be written with the entire life cycle of the submission in 
mind. 
For instance, if you decide to consolidate module 2.3 
(Quality Overall Summary), any updates to drug substance 
sections will require the resubmission of this entire module 
rather than just the pertinent information. 
As a general rule, a more granular structure should be 
considered in order to avoid issues throughout the lifecycle 
of the application. The “M4 Organization of the Common 
Technical Document for the Registration of Pharmaceuticals 
for Human Use” can be used as a reference to determine the 
permitted granularity. 
Clinical Study Reports 
Even experienced teams can encounter problems when 
determining the best way to structure a clinical study report 
(CSR) within the eCTD. Should it be submitted as a single 
document? If splitting it up, what is the proper way to group 
the sections? 
The eCTD structure for Module 5 follows the levels outlined 
in “The Comprehensive Table of Contents Headings and 
Hierarchy.” Although legacy CSRs can be submitted as one 
document, the current recommendation is to divide CSRs 
into sections: synopsis, report body, and individual 
appendices (i.e., Section 16 of the CSR separated to 3rd level 
headings). 
Preparing a CSR in this format allows reviewers to more 
easily navigate the large amount of information, leading to 
more efficient reviews. In addition, by dividing the report 
into sections, changes can be more easily tracked, as the 
entire report does not need to be replaced if only one section 
is updated. 
Report Numbering 
Every study report, both nonclinical and clinical, is required 
to have a study ID and title inserted into the submission. As 
such, it is important to ensure that all reports have a unique 
ID associated with them prior to sending to your publishing 
team. This typically becomes an issue when study data spans 
across multiple reports, such as an initial clinical study and 
associated population PK analyses. If a population PK 
analysis is being conducted for a specific clinical study, the 
population PK report should receive a unique study ID to 
ensure that the analysis is distinct from the general clinical 
study report. This also helps to ensure that any cross 
references in summary sections are clear as to the content 
being referenced. 
Annual Reports 
Back in paper days, the annual report was often written as a 
single document; however, the current granularity in “The 
Comprehensive Table of Contents Headings and Hierarchy” 
outlines multiple sections for annual reports. 
While it may be tempting for sponsors to continue authoring 
the annual reports as one document, the structure of the 
eCTD does not easily allow for this approach and can lead to 
validation errors, putting the application at risk of a 
technical rejection. 
If written as a single document, publishers may attempt to 
avoid validation issues by placing the annual report within a 
single node corresponding to one of the annual report 
sections (e.g., Summary for Nonclinical Studies). However, 
this approach risks confusion during the review, as the 
content will not properly align with the node description. 
Hyperlinking 
One of the most common issues that publishers encounter is 
attempting to hyperlink to a section and realizing that the 
section either does not exist or that it cannot be linked. Some 
of this is due to typographical errors during document 
authoring; however, many instances occur due to a lack of 
understanding by the authors of what content can actually 
be linked. As a general rule, hyperlinks can only be made to 
individual documents and not to section folders. For 
example, a frequent mistake when hyperlinking is 
referencing a section that is of a higher level of granularity 
than that to which the documents are written. Some 
examples include: 
 Referencing the module for single dose toxicity studies 
(i.e., 4.2.3.1) rather than the specific study 
 Referencing module 3.2.P.3 as a whole rather than the 
specific relevant section(s) (e.g., 3.2.P.3.1) 
The “Comprehensive Table of Contents Headings and 
Hierarchy” and “M4 Organization of the Common Technical 
Document for the Registration of Pharmaceuticals for 
Human Use” can be used to determine permitted levels 
within an application. 
The primary technical components are:  
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 A high level folder structure (required)  
 An EXtensible Markup Language (XML) “backbone" file 
which provides metadata about content files and 
lifecycle instructions for the receiving system. 
 An optional lower level folder structure 
(recommended folder names are provided in 
respective modules of the eCTD specification below)  
 Associated document type definitions (DTDs) and style 
sheets that support the presentation and navigation 
e-CTD ready document 
It is important that eCTD ready documents are prepared by 
authoring them in eCTD compliant templates. If this is not 
undertaken, a large amount of the “publishing time” is spent 
in document reformatting. 
Guidance on the preparation of eCTD ready documents is 
provided below. 
a) File Organisation for the eCTD (Granularity) 
Refer ICH Topic M 4 Common Technical Document for the 
Registration of Pharmaceuticals for Human Use. Table 5 and 
Table 6 describe the levels in the eCTD hierarchy at which 
files should be placed and whether single or multiple 
documents are appropriate at each point. The tables 
describe Modules 2 and 3 with respect to the drug 
substance. For creation and maintenance of the files, the 
storage location does not have to be considered. The 
hierarchy structure will be applied during the compilation of 
the dossier. 
b) Specification for Submission Formats 
In general, documents that are provided in the different 
modules should be formatted as defined by the ICH Common 
Technical Document. Here it is described how files should be 
constructed for inclusion in the eCTD.Document) 
specification. 
The eCTD submission is composed of the following: 
Directory structure 
 XML eCTD instance 
 Content files 
 Directory structure 
The directory structure is a structure of directories and files. 
There should be a reasonable maximum number of entries 
(directories and files) per directory. The directory structure 
should follow the rules below. The files could be in several 
formats as specified below. 
The name of the files and directories are identifiers. They 
should be short. The file names are not intended to convey 
meta-data, though some meaning in the name helps (i.e. no 
random names) 
Recommended, but optional, names for directories and files 
are provided in appendix 4. Any directory names and file 
names that are added to the eCTD (Electronic Common 
Technical Document) submission by the applicant should be 
descriptive, logical and brief. 
XML eCTD instance 
The instance is in the submission sequence number 
directory. The submission sequence number directory 
should contain at least two files and one or more directories. 
One of the files in the submission sequence directory should 
be the instance and the other should be the MD5 checksum 
of the instance. The instance is the starting file for the 
processing by an XML (Extensible Markup Language) 
processor. The intention is to have links from the leaf 
elements of the instance to the files in the ECTD (Electronic 
Common Technical Document) submission as opposed to 
creating a single XML (Extensible Markup Language) 
document that contains the entire ECTD (Electronic 
Common Technical Document) submission. The instance 
also contains meta-data at the leaf level. 
eCTD template 
The ICH (International Conference on Harmonization) 
website (http://estri.ich.org/eCTD) includes an empty ECTD 
(Electronic common Technical Document) folder template as 
an example of an ECTD (Electronic Common Technical 
Document) submission folder structure. It shows all of the 
possible modules 2-5 folders as defined in appendix 4 and 
can be populated with the applicant data and edited as 
appropriate (i.e. adding additional folders or removing 
unnecessary folders). The applicant should still add the 
relevant regional module 1 folders and content, add the 
appropriate utility folders and content, and create the XML 
(Extensible Markup Language) index files to complete a valid 
ECTD (Electronic Common Technical Document) 
submission. The file formats included in this section are 
those formats that are commonly used in electronic 
submissions. 
File naming 
File names, including the extension, must not exceed 64 
characters. Also folder names must not exceed 64 characters 
and the total file folder path length must not exceed 180 
characters. Counting starts from the first digit of the 
sequence number in the sequence number folder name. 
PDF 
PDF is accepted as a standard for documents defined in this 
specification. Adobe Portable Document Format (PDF) is a 
published format created by Adobe. It is not necessary to use 
a product from Adobe or from any specific company to 
produce PDF documents. PDF is accepted as a standard for 
documents defined in this specification. 
To ensure that PDF files can be accessed efficiently, PDF files 
should be no larger than 50 Megabytes. The files should be 
saved “optimized”. 
Version 
Agencies should be able to read all PDF files with version 4.0 
or higher of the Acrobat Reader. Agencies should not need 
any additional software to read and navigate the PDF files. 
Fonts 
Agencies cannot guarantee the availability of any fonts 
except Times New Roman, Arial and Courier and fonts 
supported in the Acrobat product set itself. Therefore, all 
additional fonts used in the PDF files should be embedded to 
ensure that those fonts would always be available to the 
reviewer. When embedding fonts, all characters for the font 
should be embedded, not just a subset of the fonts being 
used 
The main role of eCTD in pharmaceutical industry is 
regulatory submissions. And it is done by harmonizing the 
blueprint and module-based format of pharmaceutical 
submission applications. This kind of submission ensures 
convenient and faster filing of applications. This interface is 
also upgraded by the ICH at regular intervals so as to make it 
more user friendly. 
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For instance, in February 2015, ICH’s M8 expert working 
group (EWG) released a draft implementation guide for ICH 
eCTD v4.0. It was the first major version change after the 
release of v3.0 in 2003. 
Advantages using eCTD 
 eCTD is built on acknowledged standards that haven’t 
changed much in all these years in integrating ICH 
requirements 
 Regulatory tools used to review submissions have been 
upgraded and hence offer sturdy performance 
 It follows a common format for both US & Europe with 
relatively simple changes ( Module 1 and STF 
acceptance) 
 The life cycle offers detailed submission history along-
with easy knowledge transfer for product 
 Consolidated formation offers transparency to 
submissions – 
 Simple tools are used for -Publishing Submissions 
 Method is quite similar to paper work 
 Share the updates with multiple Local affiliates 
involved in the submission processes 
 Viewer is not required during the submission process 
 Affordable implementation 
eCTD challenges 
As eCTD format has become mandatory in the key markets, 
it has become essential for the companies to conceive a 
unified environment that aids the lifecycle of every kind of 
inherent submission. In this way, they can effortlessly 
manage the exhaustive system of accumulating, acclaiming, 
releasing and documenting new drug/medical device 
applications. 
Other eCTD challenges 
 Requires cutting edge technology and seasoned staff 
 Not all the content is in a standard format. Hence 
standardization is required 
 Regional differences seen in hyperlinking, 
bookmarking and PDF version 
 Difficult to implement last minute changes 
 Product knowledge is lost if the concerned employee 
quits 
 Local affiliates have limited access to create or 
customize 
 validation rules vary from region to region 
 Baseline submissions are costly and likely to be of 
limited value 
 Life-cycle management  is challenging 
 Differences seen in authentication of different regions 
 Consolidated approach to drafting of dossier 
 
Challenges faced by life sciences companies in 
eCTD submissions 
In spite of all the benefits offered by the standardized 
framework of eCTD, there are still some setbacks with this 
kind of submission format that makes it quite a challenge for 
the life sciences companies. The major challenge is to find 
the regulatory tools that support the software adhering to 
the eCTD submission requisites. 
In order to successfully carry out the eCTD submission, 
pharmaceutical companies must grasp all documents, 
including assortments, responses to questions, modifications 
and restorations in a consistent electronic format. 
The pharmaceutical companies should use a primary 
software product to manage the integrated regulatory data 
and regulatory submissions process. 
Risks involved in eCTD publishing 
As the move from paper-based to eCTD submissions 
continues around the world, a multitude ofchallenges faces 
regulatory departments. But there are simple steps you can 
take to avoid common problems, which at best can increase 
the cost of or cause delays to your submission’s approval, 
and at worst result in receipt of a Refusal To File. 
Your submission publishing might be conducted by a 
dedicated, in-house department located in the same office or 
on the other side of the globe, or you might utilize third-
party service providers. Your publishers might be highly 
experienced regulatory consultants with chemistry degrees, 
or specialized staff with administrative, IT or creative 
backgrounds. Whatever the case, busy publishing teams 
typically encounter the following 10 problems. Find out 
what you can do to avoid these problems and prevent or at 
least mitigate the risks of your eCTD publishing project. 
Source document incompatibility 
Today’s electronic publishing software greatly speeds up the 
publishing process by scanning source documents to 
automatically extract information to use as navigational aids 
in the published output. In this process, which differs among 
file types (Word, PDF, etc.) and tools from different vendors, 
source files are scanned and elements such as internal 
document links, existing bookmarks and heading/outline 
styles are processed and collected into the software’s 
database to create bookmarks and hyperlinks in the 
published output. If source files are not set up as the 
publishing software expects them to be, this process can be 
impaired and extra time may be required post publishing to 
manually add navigational elements. In companieswhere the 
whole submission preparation process (stats, medical 
writing, regulatory affairs, publishing, quality control, etc.) is 
conducted in house, setting up strict procedures and 
templates ensures the success of this process. However, if 
any of these functions is conducted externally, challenges 
increase and it is worth considering the following tips: 
 Set up and use standard procedures, templates and 
forms, and distribute these to any externalservice 
providers. 
 Publishing departments/providers should document 
and distribute the specifications andexpectations for 
source files to the concerned parties. 
 Always ensure your source files are tested in the 
publishing software well before final publishing is 
scheduled. 
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Insufficient or conflicting information for 
publishers 
Depending upon the experience of your regulatory affairs 
and publishing staff and the lines of responsibility between 
them, critical information required in the publishing process 
might be unclear or ambiguous to publishers even though it 
is included in the content of your submission. It is prudent to 
provide all expected information to the publisher, however 
obvious this information may seem.By way of example, eCTD 
submissions rely heavily on the use of metadata, which 
provide additionalinformation about elements. In some 
cases, these metadata are included in critical capacities such 
as folder paths in the final eCTD. Providing this information 
to publishers at the same time as the source files using well-
designed procedures and forms is an easy way to prevent 
potential rework. It is fairly safe to say that ambiguity is the 
publisher’s biggest enemy. If information is missing, 
progress is usually halted while the information is sought. 
However, if information is provided, but is ambiguous or 
conflicting, there is a real risk of the publisher’s interpreting 
the information incorrectly and the error may not be 
discovered until too late, requiring major rework. 
Incorrect document versions  
From a publisher’s perspective, there is nothing more soul-
destroying than working for days (or weeks) to complete 
publishing of a submission only to be informed that a wrong 
document or document version has been used. 
Unfortunately, all too often this means not only a large 
amount of rework but also the loss of full confidence in the 
integrity of the published submission, requiring more-
intensive QC reviews. Publishing groups that utilize closed 
document management systems (DMS) in their publishing 
workflows generally avoid this problem because only those 
documents and/or versions marked as approved are 
available for publishing. Groups that use file shares for 
publishing repositories are more susceptible to this type of 
problem and therefore require far more stringent 
procedures. 
Short publishing timelines 
Submission publishing usually occurs at the end of a very 
long process. Time lost in previous stages of the process 
often is expected to be recovered during publishing. This 
poses little problem to those with access to large publishing 
departments or providers that can simply add more 
resources to reduce the time required on critical path. In 
smaller publishing operations where add- ing extra 
resources is not possible, aggressive timelines usually result 
in stressed publishers who are far more likely to produce 
error-laden submissions. It is sensible to allow extra time 
not only for the possibility of delay but also for other 
contingencies such as illness and problems with legacy files. 
However, one of the most effective ways of mitigating risks 
to publishing timelines is to operate an incremental build 
policy, where modules or sections of your submission are 
published independently.Some parts of a submission 
normally are available for publishing weeks or even months 
before final publishing is scheduled to begin, and any 
possibility of publishing these sections outside the critical 
path will help adhere to the target time line. 
Nonlinear delays 
Not only are delays sometimes inevitable, (although they can 
be planned for, and in some cases mitigated), but they also 
can result in non- linear effects on the submission timeline. 
For example, a delay of one or two days can be carried 
though the project and, if extra resources cannot be utilized, 
will result in a sub- mission that is one or two days late. But 
in other cases, especially where third-party providers are 
involved, delays of just a day or two may result in far more 
serious consequences. If the slot for publishing the project 
cannot be moved back by even a day or two due to conflicts 
with other scheduled projects, the one- or two-day delay 
may end up becoming a one- or twoweek (or worse) delay. 
Inappropriate granularity  
It has often been said that that eCTD publish-ing begins with 
the author because a document produced using a quality 
template with the appropriate level of granularity has such a 
huge effect on publishing. If you plan to submit a section as 
multiple leaves, these leaves should be supplied as the 
corresponding number of source documents rather than 
being rolled up into a single file for splitting during 
publishing. Every source document that must be sent back 
for reformatting is another small opportunity for the project 
to be delayed. 
Technical problems with legacy files 
Because some information may be produced many years 
prior to inclusion in a submission using outdated software 
and equipment, many opportunities exist for errors to 
surface during publishing. Although legacy files may have 
been printed without issue in the past, electronic publishing 
is extremely efficient in highlighting technical issues, often at 
the most critical time. These issues are generally not difficult 
to resolve, although they can be very time-consuming. Here, 
the most important tool in the publisher’s toolbox is time, 
and by publishing submissions using incremental builds, 
these problems can be addressed well before they have 
opportunity to cause a delay. 
Quality Control reviewing at the right point  
By the time publishing begins, source file con- tent should be 
final and approved, as changing a document during the 
publishing process can have a devastating effect on the 
project timeline. Set clear QC points throughout the project 
but ensure those points are appropriate to the task:  
• All source documents should be quality checked before 
entering the publishing workflow.  
• The submission structure (the assembly/outline) within 
the publishing software should be independently reviewed 
prior to publishing.  
• All published PDF files should be reviewed on screen.  
• Check bookmarks and links in published PDF files.  
• Always validate and conformity-check eCTD submissions 
prior to submission.  
• Independently check all submission media and packaging 
prior to sealing and dispatch. 
Inappropriate validation process 
One of the real advantages of the eCTD is the ability to check 
its technical conformity upon submission. This means that 
both the applicant and the agency can be sure - from a 
technical perspective that the eCTD conforms to the 
specifications of the guide- lines under which it is being 
submitted. Conformity can be determined within days, or 
even hours, of being submitted, rather than the weeks or 
sometimes months required with paper submissions. 
But this process has another advantage. Although the eCTD 
is considered an open standard and can, in theory, be 
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produced and viewed using software from any vendor, in 
most cases the actual software used by the agency is also 
available to the applicant. This means that prior to 
submitting your eCTD to, say, the European Medicines 
Agency, you can validate it using the same software the 
agency uses (EursValidator) and view the same conformity 
reports on which it bases acceptance of the submission. As 
long as the electronic transfer of the files to the agency does 
not introduce any corruptions, you can be 100% confident 
that your submission will be acceptable (from a technical 
perspective) to the agency. 
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